Primary central nervous system lymphoma (PCNSL) is a central nervous system-confined non-Hodgkin lymphoma (NHL), with the pathological diagnosis being mainly diffuse large B-cell lymphoma.
Lymphoma
On May 30, 2024, Bristol Myers Squibb announced that the U.S. FDA has approved the expanded indication of its CAR-T therapy Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including those who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.
On Thursday, May 31, 2024, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), making this CD19-targeted cellular therapy the broadest approved for B-cell malignancies.
On May 16, 2024, the U.S. Food and Drug Administration (FDA) announced accelerated approval for the expanded indication of Breyanzi, Bristol Myers Squibb’s CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Breyanzi was approved by the U.S. FDA on February 5, 2021, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy developed by the American pharmaceutical company Bristol Myers Squibb (BMS) for the first-line treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after treatment.
Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor T cell (CAR-T) therapy, developed by Bristol Myers Squibb (BMS), has made significant strides in the field of cancer treatment since its initial FDA approval in 2021.